ERK Modulators Patent - Gen1E Lifesciences, Cancer Treatment
Summary
USPTO granted patent US12595243B2 to GEn1E Lifesciences Inc. covering modulators of extracellular signal-regulated kinase (ERK) for treating cancer and pulmonary diseases. The patent includes 17 claims on the chemical compounds and pharmaceutical compositions. Inventors are Adam Galan, Ritu Lal, and Chakk Ramesha.
What changed
USPTO granted patent US12595243B2 for ERK modulators developed by GEn1E Lifesciences Inc., covering pharmaceutical compositions and methods of use for treating cancer and pulmonary diseases. The patent, classified under CPC codes C07D 333/48, A61P 35/00, and A61K 31/381, contains 17 claims. The filing date was October 18, 2024, with the grant becoming effective April 7, 2026.
For pharmaceutical companies and biotechnology researchers, this patent establishes exclusive rights for the assignee in the US market for ERK modulator applications. Competitors developing similar extracellular signal-regulated kinase modulators for cancer treatment should evaluate potential infringement risks and consider licensing negotiations. Academic and commercial research programs focusing on ERK pathway inhibition may need to establish design-around strategies or seek permission from GEn1E Lifesciences.
What to do next
- Review patent claims for potential licensing opportunities
- Assess Freedom to Operate for ERK-related research programs
- Monitor for related patent family publications
Archived snapshot
Apr 7, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Modulators of extracellular signal-regulated kinase
Grant US12595243B2 Kind: B2 Apr 07, 2026
Assignee
GEn1E Lifesciences Inc.
Inventors
Adam Galan, Ritu Lal, Chakk Ramesha
Abstract
Modulators of extracellular signal-regulated kinase, pharmaceutical compositions thereof, and uses of the compound and pharmaceutical compositions thereof for treating cancer and pulmonary diseases are disclosed.
CPC Classifications
C07D 333/48 A61P 35/00 A61K 31/381
Filing Date
2024-10-18
Application No.
18920162
Claims
17
Related changes
Get daily alerts for ChangeBridge: Patent Grants - Pharma (A61K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ChangeBridge: Patent Grants - Pharma (A61K) publishes new changes.